
Antibody Drug Conjugates
See the science behind Genentech's continued development of antibody drug conjugates (ADCs) and the potential of delivering highly potent cytotoxins directly to malignant B cells and other tumors.1,2

Individualized Neoantigen-Specific Immunotherapy (iNeST)
Learn more about the potential of inducing antitumor immune responses through our investigational Individualized NeoAntigen Specific Immunotherapy (iNeST).3

Monoclonal Antibodies
Read more about our diverse approaches to transforming the innate ability of antibodies into potential therapeutic agents against cancer.4

Small Molecules
Read more about our continued research in targeting intracellular tumor mechanisms to interrupt pathway dysregulation.5,6

Bispecific Antibodies
Discover our unique bispecific antibody design technologies and the innovative method of harnessing the immune system to fight cancer through the simultaneous binding of T cells and tumor-cell antigens.7,8